MyFinsight
Home
Blog
About
Contact
Download
Download image
Proceeds from issuances
of common stock...
$147,853K
Proceeds from issuances
of common stock...
$12,530K
Net cash provided by
financing activities
$160,383K
Net cash increase
(decrease) for the period
$7,568K
Canceled cashflow
$152,815K
Maturities of marketable
securities
$42,050K
Stock-based compensation
$7,847K
Accounts payable,
accrued expenses and...
$1,195K
Depreciation
$138K
Right-of-use assets and lease
liabilities, net
$17K
Net cash provided by
(used in) investing...
-$120,244K
Net cash used in
operating activities
-$32,571K
Canceled cashflow
$42,050K
Canceled cashflow
$9,197K
Purchases of marketable
securities
$162,206K
Net loss
-$39,305K
Purchases of property and
equipment
$88K
Prepaid expenses and
other assets
$2,438K
Accretion of marketable
securities, net
-$25K
Back
Back
Cash Flow
Tyra Biosciences, Inc. (TYRA)
Tyra Biosciences, Inc. (TYRA)
source: myfinsight.com